The influence of 5-year therapy with tibolone on the lipid profile in postmenopausal women with mild hypercholesterolemia

References

• Castelo-Branco C, Vicente JJ, Figueras F, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000;34:161–8
   Google Scholar
• Egarter C, Huber J, Leikermoser R, et al. Tibolone versus conjugated estrogens and sequential proges-togen in the treatment of climacteric complaints. Maturitas 1996;23:55–62
   PubMed Web of Science ®Google Scholar
• Botsis D, Kassanos D, Kalogirou D, et al. Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: a compar-ison. Maturitas 1997;26:57–62
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321–33
   Google Scholar
• Palacios S. Tibolone: what does tissue specific activity mean? Maturitas 2001;37:159–65
   PubMed Web of Science ®Google Scholar
• Jensen J, Nilas L, Christansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990;12:321–31
   PubMed Web of Science ®Google Scholar
• Milner MH, Sinnott MM, Cooke TM, et al. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estro-gen—progestin. Obstet Gynecol 1996;87:593–9
   PubMed Web of Science ®Google Scholar
• Davis SR. The effects of tibolone on mood and libido. Menopause 2002;9:162–70
   PubMed Web of Science ®Google Scholar
• Wu MH, Pan HA, Wang ST, et al. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 2001;4:314–19
   PubMedGoogle Scholar
• Thiebaud D, Bigler JM, Renteria S, et al. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyproges-terone acetate versus tibolone. Climacteric 1998;1: 202–10
   PubMedGoogle Scholar
• Stevenson JC, Crook D, Codsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83–90
   Google Scholar
• Crook D, Jackson G. Tibolone's cardiovascular risk profile. Orgyn (special issue) 1999;1:39–40
   Google Scholar
• Castelo-Branco C, Casals E, Figueras F, et al. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins Al and B. Menopause 1999;6:92–7
   Google Scholar
• Koh KK, Ahn JY, Jin DK, et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmeno-pausal women: a randomized, double-blind, placebo-controlled, crossover study. Arterioscler Thromb Vasc Biol 2003;23:1889–94
   PubMed Web of Science ®Google Scholar
• Barnes JF, Farish E, Rankin M, et al. A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors. Atherosclerosis 2002;160: 185–93
   PubMed Web of Science ®Google Scholar
• Lloyd G, McGing E, Cooper A, et al. A randomized placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. J Hum Hypertens 2000;14:99–104
   PubMed Web of Science ®Google Scholar
• Ossewaarde ME, Dallinga-Thie GM, Bots ML, et al. Treatment with hormone replacement therapy lowers remnant lipoprotein particles in healthy postmenopausal women: results from a randomized trial. EurJ Clin Invest 2003;33:376–82
   PubMed Web of Science ®Google Scholar
• Hanggi W, Lippyner K, Riesen W, et al. Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipopro-tein(a): a randomized study. Br J Obstet Gynaecol 1997;104:708–17
   PubMedGoogle Scholar
• Palomba S, Affinito P, Di Carlo C, et al. Long-term administration of tibolone plus gonadotropin-re-leasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone, and lipid profiles. Fertil Steril 1999;72:889–95
   PubMed Web of Science ®Google Scholar
• Trichopoulou A, Vasilopoulou E. Mediterranean diet and longevity. Br J Nutr 2000;84(Suppl 2):S205–9
   PubMed Web of Science ®Google Scholar
• Adamopoulos PN, Papamechael C, Fida H, et al. Precursors of atherosclerosis in a random sample from a Hellenic population: the Athens Study. J Cardiovasc Risk 1995;2:525–31
   PubMedGoogle Scholar
• Trichopoulou A, Katsouyanni K, Gnardellis C. The traditional Greek diet. Eur J Clin Nutr 1993;47(Suppl 1):S76–81
   PubMedGoogle Scholar
• Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas 1998;30:295–305
   PubMed Web of Science ®Google Scholar
• Simoncini T, Genazzani AR. Tibolone inhibits leukocyte adhesion molecule expression in human endothelial cells. Mol Cell Endocrinol 2000;162:87–94
   PubMed Web of Science ®Google Scholar
• Winkler UH, Altkemper R, Kwee B, et al. Effects of tibolone and continuous combined hormone repla-cement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000;74:10–19
   PubMed Web of Science ®Google Scholar
• Coelingh B. Clinical experience with tibolone, a tissue-specific hormone. Gynecol Endocrinol 1997;11(Suppl 1):57–62
   Google Scholar
• Gallagher JC, Baylink DJ, Freeman R, et al. Prevention of bone loss with tibolone in postme-nopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding stu-dies. J Clin Endocrinol Metab 2001;86:4717–26
   PubMed Web of Science ®Google Scholar
• Reginster JY, Agnusdei D, Gennari C, et al. Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women. Gynecol En-docrinol 1999;13:361–8
   PubMed Web of Science ®Google Scholar
• Volker W, Coelingh Bennink HJ, Helmond FA. Effects of tibolone on the endometrium. Climacteric 2001;4:203–8
   PubMedGoogle Scholar
• Rymer J, Fogelman I, Chapman MG. The in-cidence of vaginal bleeding with tibolone treatment. Br J Obstet Gynaecol 1994;101:53–6
   Google Scholar
• Gompel A, Siromachkova M, Lombet A, et al. Tibolone actions on normal and breast cancer cells. Eur J Cancer 2000;36(Suppl 4):S76–7
   Google Scholar
• Colacurci N, Fornaro F, De Franciscis P, et al. Effects of different types of hormone replacement therapy on mammographic density. Maturitas 2001;40:159–64
   PubMed Web of Science ®Google Scholar
• Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. AmJ Obstet Gynecol 2002;186:717–22
   Web of Science ®Google Scholar
• Egarter C, Eppel W, Vogel S, et al. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas 2001;40:165–71.
   PubMed Web of Science ®Google Scholar